Keyword: Bristol-Myers Squibb
Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.
BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.
Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.
The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.
Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?
With one member of its "big 5" already approved, Celgene has just received a second with the FDA nod for blockbuster hopeful anemia med Reblozyl.
Bristol-Myers' Eliquis is keeping up with its world-beater rep, but analysts worry about I-O med Opdivo—and execs say the med faces a tough 2020.
It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.
While investors don't fancy megamergers, smaller deals in oncology could be the winning ticket, analysts have found.
Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.